1359 Broadway
Suite 1710
New York, NY 10018
United States
212 433 3791
https://zentalis.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 124
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Cameron S. Gallagher M.B.A. | Co-Founder, President, Interim CFO, Treasurer & Director | 767.69k | N/A | 1971 |
Ms. Andrea Paul J.D. | Chief Legal Officer & Corporate Secretary | 668.2k | N/A | 1982 |
Mr. Vincent Vultaggio | VP of Finance & Interim Principal Accounting Officer | N/A | N/A | 1983 |
Dr. Mark Lackner Ph.D. | Chief Scientific Officer | N/A | N/A | 1968 |
Dr. Diana F. Hausman M.D. | Chief Medical Officer & Director | N/A | N/A | 1963 |
Ms. Kimberly Freeman | Chief Strategy Officer | N/A | N/A | N/A |
Dr. Kyle Rasbach Ph.D., Pharm.D. | Chief Business Officer | N/A | N/A | 1980 |
Dr. Adrian Jubb M.D., Ph.D. | Executive Vice President of Clinical Development | N/A | N/A | N/A |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Zentalis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 8; Compensation: 10.